Drug Information
General Information | ||||||
---|---|---|---|---|---|---|
Drug ID |
DR00140
|
|||||
Drug Name |
Ezetimibe
|
|||||
Synonyms |
(-)-Sch 58235; (1-(4-fluorophenyl)-(3R)-(3-(4-fluorophenyl)-(3S)-hydroxypropyl)-(4S)-(4-hydroxyphenyl)-2-azetidinone); (3R,4S)-1-(4-fluorophenyl)-3-[(3S)-3-(4-fluorophenyl)-3-hydroxypropyl]-4-(4-hydroxyphenyl)azetidin-2-one; (3R,4S)-1-(p-Fluorophenyl)-3-((3S)-3-(p-fluorophenyl)-3-hydroxypropyl)-4-(p-hydroxyphenyl)-2-azetidinone; 1-(4-fluorophenyl)-3(R)-[3-(4-fluorophenyl)-3(S)-(4-hydroxyphenyl)-2-azetidione; 1-(4-fluorophenyl)-3(R)-[3-(4-fluorophenyl)-3(S)-hydroxypropyl]-4(S)-(4-hydroxyphenyl)-2-azetidinone; Essex brand of ezetimibe; Ezedoc; Ezetimib; Ezetimibe (JAN/USAN/INN); Ezetimibe [USAN:INN]; Ezetrol; Inegy (TN); MK-0653; MSD brand of ezetimibe; Merck brand of ezetimibe; SCH-58235; SCH58235; Sch 58235; Schering-Plough brand of ezetimibe; Vytorin (TN); Zetia; Zetia (TN); Zetia , Ezetrol, Ezetimibe; Zient
|
|||||
Drug Type |
Small molecular drug
|
|||||
Indication | Hypercholesterolemia [ICD11: 5C80.0] | Approved | [1] | |||
Therapeutic Class |
Anticholesteremic Agents
|
|||||
Structure |
|
|||||
3D MOL | 2D MOL | |||||
Formula |
C24H21F2NO3
|
|||||
Canonical SMILES |
C1=CC(=CC=C1C2C(C(=O)N2C3=CC=C(C=C3)F)CCC(C4=CC=C(C=C4)F)O)O
|
|||||
InChI |
InChI=1S/C24H21F2NO3/c25-17-5-1-15(2-6-17)22(29)14-13-21-23(16-3-11-20(28)12-4-16)27(24(21)30)19-9-7-18(26)8-10-19/h1-12,21-23,28-29H,13-14H2/t21-,22+,23-/m1/s1
|
|||||
InChIKey |
OLNTVTPDXPETLC-XPWALMASSA-N
|
|||||
CAS Number |
CAS 163222-33-1
|
|||||
Pharmaceutical Properties | Molecular Weight | 409.4 | Topological Polar Surface Area | 60.8 | ||
Heavy Atom Count | 30 | Rotatable Bond Count | 6 | |||
Hydrogen Bond Donor Count | 2 | Hydrogen Bond Acceptor Count | 5 | |||
XLogP |
4
|
|||||
PubChem CID | ||||||
PubChem SID |
10250673
, 103326446
, 104179182
, 104253290
, 104428106
, 11528896
, 117884262
, 12014979
, 124658886
, 124757411
, 124801398
, 125164215
, 126592989
, 126621626
, 126653456
, 126667079
, 127315811
, 127315812
, 127315813
, 127315814
, 127315815
, 127315816
, 127315817
, 127315818
, 127315819
, 127315820
, 127315821
, 127315822
, 127315823
, 127315824
, 128826430
, 131854738
, 134338005
, 135107180
, 14879623
, 14928749
, 26719841
, 46226990
, 46386640
, 46507625
, 49681809
, 49693660
, 50539938
, 53787196
, 57347010
, 71821424
, 7849028
, 81146074
, 92308446
, 92718207
|
|||||
ChEBI ID |
ChEBI:49040
|
|||||
TTD Drug ID | ||||||
DT(s) Transporting This Drug | BCRP | Transporter Info | Breast cancer resistance protein | Substrate | [2] | |
BSEP | Transporter Info | Bile salt export pump | Substrate | [3] | ||
MRP2 | Transporter Info | Multidrug resistance-associated protein 2 | Substrate | [4] | ||
MRP3 | Transporter Info | Multidrug resistance-associated protein 3 | Substrate | [2] | ||
OATP1B1 | Transporter Info | Organic anion transporting polypeptide 1B1 | Substrate | [5] | ||
P-GP | Transporter Info | P-glycoprotein 1 | Substrate | [6] | ||
References | ||||||
1 | Ezetimibe was approved by FDA. The official website of the U.S. Food and Drug Administration. (2019) | |||||
2 | Complex pharmacokinetic behavior of ezetimibe depends on abcc2, abcc3, and abcg2. Drug Metab Dispos. 2009 Aug;37(8):1698-702. | |||||
3 | Early identification of clinically relevant drug interactions with the human bile salt export pump (BSEP/ABCB11). Toxicol Sci. 2013 Dec;136(2):328-43. | |||||
4 | Intestinal expression of P-glycoprotein (ABCB1), multidrug resistance associated protein 2 (ABCC2), and uridine diphosphate-glucuronosyltransferase 1A1 predicts the disposition and modulates the effects of the cholesterol absorption inhibitor ezetimibe in humans. Clin Pharmacol Ther. 2006 Mar;79(3):206-17. | |||||
5 | A LC-MS/MS method to quantify the novel cholesterol lowering drug ezetimibe in human serum, urine and feces in healthy subjects genotyped for SLCO1B1. J Chromatogr B Analyt Technol Biomed Life Sci. 2006 Jan 2;830(1):143-50. | |||||
6 | Pharmacokinetic and pharmacodynamic interactions between the immunosuppressant sirolimus and the lipid-lowering drug ezetimibe in healthy volunteers. Clin Pharmacol Ther. 2010 Jun;87(6):663-7. |
If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.